insert therapeutics unidym tego bio sciences science research anti-cancer drugs RNAi therapeutics carbon-based electronics nanotechnology arrowhead pasadena california nasdaq arwr nanotechnology arrowhead pasadena california nasdaq arwr

Arrowhead Press Release Archive

July 30, 2009
Arrowhead Senior Advisors Featured in Nature and Nature Medicine Articles

July 16, 2009
Arrowhead Increases Ownership in Carbon Nanotube-based Electronics Films Subsidiary Unidym Inc. to 70%

July 10, 2009
Arrowhead Announces Private Placement of $2 Million

July 10, 2009
Arrowhead announces CFO Transition

June 23, 2009
Arrowhead Subsidiary Calando Pharmaceuticals Enters into License Agreement with Cerulean Pharma Inc.

May 15, 2009
Arrowhead Reports Second Quarter Fiscal 2009 Financial Results

March 6, 2009
Arrowhead to Transfer to The NASDAQ Capital Market

February 18, 2009
Arrowhead CEO Comments on Recent Nasdaq Letter

February 13, 2009
Arrowhead Receives Notification of Minimum Stockholders’ Equity Non-Compliance from the Nasdaq Stock Market

February 9, 2009
Arrowhead Reports First Quarter Fiscal 2009 Financial Results

January 26, 2009
Arrowhead's Majority Owned Subsidary, Unidym, Inc. Consolidates Operations

December 15, 2008
Arrowhead Reports Fourth Quarter and Full Year 2008 Financial Results

December 8, 2008
Calando Pharmaceuticals Publishes New Results of siRNA Delivery
Using Its RONDEL(TM) Technology in Sepsis

December 3, 2008
Arrowhead Raises $5.4 Million into Two Subsidiaries; Initiatives Strengthen Balance Sheet for 2009

November 19, 2008
Arrowhead CEO Provides Update on Tego Biosciences Corporation

November 17, 2008
Arrowhead Research Corporation Retains The Piacente Group, Inc. as Strategic Investor Relations Consulting Firm

November 12, 2008
Arrowhead CEO Provides Update on Nanotope, Inc.

November 4, 2008
Arrowhead CEO Provides Update on Majority Owned Subsidiary Unidym, Inc.

November 3, 2008
Calando Pharmaceuticals to Present at 19th Annual
Oppenheimer Healthcare Conference on November 4, 2008

October 31, 2008
Arrowhead Research Corporation to Present at
AeA Classic Financial Conference November 4 and 5, 2008

October 28, 2008
Arrowhead CEO Provides Update on Wholly Owned Subsidiary Agonn Systems, Inc.

October 23, 2008
Calando Pharmaceuticals Announces Completion of IT-101 Phase 1 Clinical Study

October 21, 2008
Arrowhead CEO Provides Update on Majority Owned Subsidiary Calando Pharmaceuticals Inc.

October 16, 2008
Unidym Announces a Demonstration by Samsung Electronics of
the First Color Carbon Nanotube-Based Electrophoretic Display

October 14, 2008
Arrowhead CEO Updates Stockholders

October 7, 2008
Calando Patent Issued for Active Ingredient of Lead siRNA Drug Candidate, CALAA-01

October 2, 2008
Unidym Licenses Technology for Semiconductor Applications

September 15, 2008
Calando Pharmaceuticals Announces Next siRNA Therapeutic Candidate for Oncology

September 11, 2008
CALANDO PHARMACEUTICALS PHASE II CLINICAL STUDY OPENS TO PATIENT ENROLLMENT

September 9, 2008
ARROWHEAD COMPLETES PREVIOUSLY ANNOUNCED REGISTERED DIRECT OFFERING RAISES A TOTAL OF $6.9 MILLION TO FUND OPERATIONS

August 12, 2008
UNIDYM ENTERS INTO SECOND JOINT DEVELOPMENT AGREEMENT WITH SAMSUNG ELECTRONICS TO INTEGRATE CARBON NANOTUBES INTO DISPLAY DEVICES

July 21, 2008
ALNYLAM GRANTS NEW INTERFERX(TM) INTELLECTUAL PROPERTY LICENCE TO CALANDO FOR DEVELOPMENT AND COMMERCIALIZATION OF RNAi THEARPEUTICS

July 9, 2008
ARROWHEAD FORMS NEW SUBSIDIARY TO COMMERCIALIZE ENERGY STORAGE DEVICES

June 17, 2008
ARROWHEAD SUBSIDIARY, UNIDYM, RECEIVES STRATEGIC INVESTMENT FROM ENTEGRIS

June 12, 2008
CALANDO PHARMACEUTICALS COLLABORATES WITH CITY OF HOPE TO INITIATE INVESTIGATOR SPONSORED CLINICAL TRIAL USING IT-101 IN LYMPHOMA PATIENTS

June 5, 2008
BATTELLE AND UNIDYM INC. FORM AN ALLIANCE FOCUSED ON THE USE OF CARBON NANOTUBES IN COMPOSITES

June 2, 2008
CALANDO PHARMACEUTICALS DOSES FIRST PATIENT IN siRNA PHASE I CLINICALTRIAL

May 20, 2008
UNIDYM DEMONSTRATES FIRST FULL COLOR ACTIVE MATRIX LCD USING A CARBON NANOTUBE-BASED TRANSPARENT ELECTRODE

May 19, 2008
UNIDYM'S CTO DR. PAUL DRZAIC NAMED NEW PRESIDENT OF THE SOCIETY FOR INFORMATION DISPLAY

May 16, 2008
UNIDYM TO EXHIBIT AND PRESENT AT LEADING DISPLAY CONFERENCE

May 15, 2008
ARROWHEAD EXPANDS EXECUTIVE TEAM TO BROADEN TECHNICAL AND OPERATIONAL EXPERTISE

May 13, 2008
CALANDO GRANTED BROAD PATENT RIGHTS TO RNAi TECHNOLOGY IN CHINA

May 6, 2008
ARROWHEAD SELLS SUBSIDIARY AONEX TECHNOLOGIES TO AMBERWAVE SYSTEMS FOR UP TO $7.95 MILLION PLUS ROYALTY

April 24, 2008
ARROWHEAD NANOBIOTECHNOLOGY SUBISIDARIES, CALANDO PHARMACEUTICALS AND INSERT THERAPEUTICS COMPLETE MERGER

April 22, 2008
UNIDYM INC. ANNOUNCES THE FIRST FLIGHT OF AN AIRCRAFT USING CARBON NANOTUBES FOR INCREASED FUSELAGE STRENGTH

April 21, 2008
Calando Receives FDA Approval for Phase I Clinical Trial Using a Targeted siRNA Nanoparticle Therapeutic

April 17, 2008
Insert Therapeutics to Initiate a Multinational Phase II Clinical Trial of Lead Drug Candidate IT-101 in Ovarian Cancer

March 18, 2008
UNIDYM INC. SPINS OFF ENSYSCE BIOSCIENCES INC. TO PURSUE MEDICAL THERAPEUTIC APPLICATIONS OF CARBON NANOTUBES

March 14, 2008
ARROWHEAD CEO PRESENTS 2008 OBJECTIVES

March 13, 2008
ARROWHEAD SUBSIDIARY, CALANDO PHARMACEUTICALS, SUBMITS IND FOR CLINICAL TRIAL WITH TARGETED, NANO-DELIVERED RNAi THERAPEUTIC FOR CANCER

March 12, 2008
ARROWHEAD RESEARCH SUBSIDIARY, UNIDYM, ENTERS INTO DEVELOPMENT AGREEMENT WITH NIPPON KAYAKU TO INTEGRATE CARBON NANOTUBES INTO THIN FILM SOLAR CELLS

March 5, 2008
ARROWHEAD CEO TO PRESENT OBJECTIVES FOR 2008 VIA WEBCAST FOLLOWING ANNUAL MEETING OF SHAREHOLDERS

February 28, 2008
ARROWHEAD STREAMLINES BUSINESS MODEL OF NANOBIOTECH SUBS, CALANDO PHARMACEUTICALS AND INSERT THERAPEUTICS

February 12, 2008
Arrowhead Announces the Appointment of Dr. Chad Mirkin

February 11, 2008
Arrowhead Research Subsidiary, Unidym, Ramps Up Manufacturing to Meet Carbon Nanotube Demand

January 28, 2008
Arrowhead Announces the Appointment of Dr. Mauro Ferrari to its New Board of Advisors

January 22, 2008
Arrowhead CEO Invited to Give Keynote Presentation at Rice Alliance Nanotechnology Venture Forum

back to Press Releases